B-cell lymphoma 6 protein Antibodies

B-cell lymphoma 6 protein (BCL6)

Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation that has different mechanisms of action specific to the lineage and biological purposes. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes.

In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of several genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, such as miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without causing a p53/TP53-dependent apoptotic response.

Gene Information

Human
Gene Name:	BCL6
Uniprot:	P41182
Entrez:	604

Family

Belongs to:
No superfamily

Alternative Names

B-cell CLL/lymphoma 6; B-cell lymphoma 6 protein transcript; Bcl-5; BCL5B-cell lymphoma 5 protein; Bcl6; Bcl-6; BCL6A; cys-his2 zinc finger transcription factor; LAZ3; LAZ3ZBTB27B-cell lymphoma 6 protein; lymphoma-associated zinc finger gene on chromosome 3; Protein LAZ-3; ZBTB27 ; Zinc finger and BTB domain-containing protein 27; Zinc finger protein 51ZNF51; zinc finger transcription factor BCL6S; ZNF51

Molecular Weight

Mass (kDA):
78.846 kDA

Genomic Context

Human
Location:	3q27.3
Sequence:	3; NC_000003.12 (187721377..187745472, complement)

Tissue Specificity

Expressed in germinal center T- and B-cells and in primary immature dendritic cells.

Subcellular Localizations

Nucleus.

Diseases

• Lymphoma
• B-cell Lymphomas
• Diffuse Large B-cell Lymphoma
• Neoplasms
• Chromosomal Translocation
• Lymphoma, Follicular
• Lymphoma, Non-hodgkin
• Malignant Neoplasms
• Leukemogenesis
• Burkitt Lymphoma
• Cytogenetic Abnormality
• Malignant Paraganglionic Neoplasm
• Leukemia

• Cell Transformation, Neoplastic
• Marginal Zone B-cell Lymphoma
• Hodgkin Disease
• T-cell Lymphoma
• Mucosa-associated Lymphoid Tissue Lymphoma
• Inflammation
• Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse

Interacting Proteins

• AES
• BLZF1
• Crebbp
• CUTC
• FBXO11

• GOLGA2
• HDAC4
• HDAC9
• KIFC3
• LIMS4

• SIAH1
• TRAF1
• TRIB3
• ZBTB7B
• ZMYND8

Pathways

• Pathogenesis
• Cell Differentiation
• Interphase
• Cell Cycle
• Cell Development
• Cell Proliferation
• Plasma Cell Differentiation
• Immune Response
• Germinal Center Formation
• B Cell Differentiation
• Localization
• Cell Growth
• Methylation

• Secretion
• Dna Repair
• Cell Cycle Arrest
• Cell Death
• Metaphase
• Humoral Immune Response
• T Cell Differentiation

PTMs

• Methylation
• Phosphorylation
• Acetylation
• Deacetylation
• Cleavage
• Demethylation

• Deamination
• Sumoylation
• Dephosphorylation
• Prenylation
• Ubiquitination
• Biotinylation

• Reduction

Research Areas

• Cancer
• Cell Cycle and Replication
• Tumor Suppressors

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/BCL6

Boster Bio Anti-BCL6 Marker

If you're considering using a Boster Bio Anti-BCL6 Marker to confirm BCL6 protein expression, read on for some important information. Here are the applications and validations, as well as costs. Boster has been in the business for over 20 years, and their antibody selection process is second to none. They're committed to providing high-quality antibodies at an affordable price.

Boster Bio Anti-BCL6 Marker

Boster Bio manufactures antibodies and ELISA kits to detect specific biomarkers, including BCL6. They can detect levels of the marker down to the picogram level and provide excellent sensitivity. The company also offers free technical resources for scientists. In addition to their antibodies and ELISA kits, Boster offers a variety of services to scientists. Their customer support team is available around the clock to help researchers, and the company offers technical support free of charge.

The BCL6 antibody is supplied in PBS containing 0.09% sodium azide for storage. The antibody is produced by immunization of rabbits with a synthetic peptide between 364 and 395 amino acids, which has been shown to inhibit gene silencing. The antibody can be used for detection of BCL6 in cell cultures, as well as for the identification of cancer-causing proteins.

Validation

The BCL6 marker in Boster Bio has been validated against several gene targets. These genes are known to be associated with the BCL6 repressor. Moreover, BCL6 is involved in very early events during the development of TFH cells, including establishing their phenotype. The BCL6 repressor negatively correlates with the expression of target genes.

To validate the BCL6 reactivity of BI-3802, four codons were collapsed to unique amino acid positions. The CERES score of BCL6 was measured in 559 cell lines. The BCL6-RID marker was optimized in Boster Bio based on this data. The BI-3802 interface was used to highlight residues involved in drug binding and polymerization. C84 and E41 were highlighted using magenta. G55 incorporated hydrogen atoms and were highlighted with a star.

The results of C-terminal truncation analysis indicate that the deletion of the VxP motif leads to degradation of BCL6. The results indicate that BCL61-375, BCL61-250, and BCL61-125 are degraded in the presence of BI-3802, but BCL61-125 remained stable and formed foci. Further, mutation of GSA reduces the reactivity of BCL6-BTB peptide.

The BCL6 polymerization activity of BI-3802 was inhibited in vitro by mutating R28 and Y58 to alanine. It was also observed that mutation of R28 to alanine decreased the BCL6 polymerization, and the mutation of E41 to alanine impaired the formation of foci. Therefore, unbiased mutagenesis was used to validate the BCL6 reactivity of BI-3802.

Further, the molecular details of BCL6 are now available. Understanding the mechanisms of BCL6 activity could facilitate the development of therapeutics. Indeed, abnormal BCL6 activity is known to cause several cancers, including leukemia and lymphoma. These new details will allow optimizing strategies to address the underlying mechanisms. In the meantime, this information will enable researchers to better target specific treatments for BCL6 malignancies.

Furthermore, BCL6 polymerization enables the interaction between BCL6 and SIAh2, thereby improving its ubiquitination activity. Further, BCL6 is also able to interact with SIAh2, thereby improving its degradation. For these reasons, BCL6 polymerization in Boster Bio may be a useful tool to predict the activity of specific therapeutic agents.

Applications

The BCL6 marker is a highly specific and sensitive biomarker for endometrial dysfunction. The most common endometrial dysfunction is endometriosis, but other disorders, such as hydrosalpinx, can also be detected using the BCL6 marker. This biomarker can also be used to screen a woman for endometriosis and hydrosalpinx before implantation.

As a biomarker for endometriosis, BCL6 is particularly sensitive to mild forms. This makes BCL6 an excellent candidate for use in this condition. Furthermore, it is associated with progesterone resistance and endometrial dysfunction, making it a potentially useful biomarker for this condition. Regardless of the method, the BCL6 gene is a promising candidate for this condition.

As an immunostaining marker, BCL6 can distinguish classical Hodgkin lymphoma from nodular lymphocyte-predominant lymphoma. Classical Hodgkin lymphomas are Bcl-6 negative, while NLPHL cells contain large (L&H) cells. Anti-Bcl-6 staining is rarely effective in separating mantle-cell lymphomas or MALT lymphomas.

Furthermore, BCL6 is expressed in several stages of the menstrual cycle. It was found that the expression of BCL6 in endometrial tissues of women with endometriosis was dramatically higher in the proliferative than in eutopic endometrium. However, the BCL6 protein expression was low in the secretory phase. Nevertheless, BCL6 expression was highly elevated in the proliferative phase.

Cost

The cost of the BCL6 marker varies depending on the lab used. The cost of a BCL6 marker test can run as high as $400, depending on the lab used. The price is dependent on the quality of the test and the number of samples. The test is generally considered a high-quality marker, and the price is fair given its use. For this reason, it is not recommended for routine use.